Form 4 ELI LILLY & Co For: Feb 01 Filed by: Van Naarden Jacob
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
February 5, 2026 12:35 PM ESTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $1,281.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "LLY already has a broad footprint in the obesity landscape - With what we believe to be the best drug incretin currently and an increasing uptake trend as indicated by scripts + strong data from Retatrutide + additional life cycle management strategies from LLY. We expect LLY to remain the market leader in the obesity space. We model WW peak Lilly revenues from obesity of 78B vs. $43B cons in year 2036E (our model terminal... More
